BRIEF—Artios Pharma announces $84 million series B financing

Artios Pharma, a specialist in DNA damage response (DDR) therapy, has announced the conclusion of an $84 million series B funding round.

The capital was raised by major healthcare investors including the venture arms of Pfizer, Merck & Co, AbbVie and Novartis.

Artios, an oncology specialist, was founded in 2016 and is based in Cambridge, UK. It was founded by the investment firm SV Life Sciences and Cancer Research UK.